Extracorporeal Photopheresis for Medicare Recipients of Lung Allografts
Evidence level: registry entry; no results posted
A registered phase 3 study of extracorporeal photopheresis (ECP) for progressive bronchiolitis obliterans syndrome in Medicare-eligible lung allograft recipients, sponsored by Washington University School of Medicine.
As of . Primary source: ClinicalTrials.gov NCT02181257.
Summary
The ClinicalTrials.gov entry describes an interventional study run under a Medicare Coverage with Evidence Development decision. It enrols patients with refractory or newly diagnosed bronchiolitis obliterans syndrome, with a retrospective chart-review comparator group. The registry lists actual enrolment of 280. The registry states that enrolment ceased in April 2022 and lists the primary outcome for refractory BOS as the change in the rate of FEV1 decline. No results are posted.
Details
- registry
- ClinicalTrials.gov
- registryId
- NCT02181257
- registryTitle
- Extracorporeal Photopheresis for the Management of Progressive Bronchiolitis Obliterans Syndrome in Medicare-Eligible Recipients of Lung Allografts
- acronym
- ECP
- sponsor
- Washington University School of Medicine
- registryStatus
- active not recruiting
- phase
- Phase 3
- studyType
- interventional
- enrolment
- 280 (actual)
- startDate
- 2015-01 (type not stated)
- primaryCompletionDate
- 2027-04 (estimated)
- intervention
- Extracorporeal Photopheresis (ECP) (combination product); No intervention in the SOC / Retrospective Chart review. (other)
- condition
- Bronchiolitis Obliterans Syndrome (BOS)
- registryLastUpdatePosted
- 2026-04-06
- registryRead
- 2026-10-10
Sources and links
Related
Links from this record
Linked from (derived)
Known gaps in this record
- results: none posted in the registry
- participating centres and investigators: not recorded
- link to a CLADsolve centre record: not made
Information resource only. Not medical advice. Not a substitute for the care of the patient's transplant team.